Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study-Reference-Cited by-同舟云学术

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Published:2021-11 Issue: Volume: Page:
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Ismail Nazir Ahmed,Omar Shaheed Vally,Moultrie Harry,Bhyat Zaheda,Conradie Francesca,Enwerem M,Ferreira Hannetjie,Hughes Jennifer,Joseph Lavania,Kock Yulene,Letsaolo Vancy,Maartens Gary,Meintjes Graeme,Ngcamu Dumisani,Okozi Nana,Padanilam Xavier,Reuter Anja,Romero Rodolf,Schaaf Simon,te Riele Julian,Variava Ebrahim,van der Meulen Minty,Ismail Farzana,Ndjeka Norbert

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference25 articles.

1. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study;Schnippel;Lancet Respir Med,2018

2. Culture conversion in patients treated with bedaquiline and/or delamanid: a prospective multi-country study;Franke;Am J Respir Crit Care Med,2020

3. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study;Borisov;Eur Respir J,2017

4. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study;Zhao;Clin Infect Dis,2019

5. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen;Ndjeka;Eur Respir J,2018

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience;The Lancet Infectious Diseases;2024-09

2. MmpR5 protein truncation and bedaquiline resistance in Mycobacterium tuberculosis isolates from South Africa: a genomic analysis;The Lancet Microbe;2024-08

3. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study;The Lancet Global Health;2024-08

4. Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial;BMJ Open;2024-07

5. Combating antimicrobial resistance in malaria, HIV and tuberculosis;Nature Reviews Drug Discovery;2024-05-15